Cargando…

Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis

The applications of liquid biopsy have attracted much attention in biomedical research in recent years. Circulating cell-free DNA (cfDNA) in the serum may serve as a unique tumor marker in various types of cancer. Circulating tumor DNA (ctDNA) is a type of serum cfDNA found in patients with cancer a...

Descripción completa

Detalles Bibliográficos
Autores principales: Gu, Yulan, Wan, Chuandan, Qiu, Jiaming, Cui, Yanhong, Jiang, Tingwang, Zhuang, Zhixiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004305/
https://www.ncbi.nlm.nih.gov/pubmed/32027658
http://dx.doi.org/10.1371/journal.pone.0224001
_version_ 1783494694635831296
author Gu, Yulan
Wan, Chuandan
Qiu, Jiaming
Cui, Yanhong
Jiang, Tingwang
Zhuang, Zhixiang
author_facet Gu, Yulan
Wan, Chuandan
Qiu, Jiaming
Cui, Yanhong
Jiang, Tingwang
Zhuang, Zhixiang
author_sort Gu, Yulan
collection PubMed
description The applications of liquid biopsy have attracted much attention in biomedical research in recent years. Circulating cell-free DNA (cfDNA) in the serum may serve as a unique tumor marker in various types of cancer. Circulating tumor DNA (ctDNA) is a type of serum cfDNA found in patients with cancer and contains abundant information regarding tumor characteristics, highlighting its potential diagnostic value in the clinical setting. However, the diagnostic value of cfDNA as a biomarker, especially circulating HPV DNA (HPV cDNA) in cervical cancer remains unclear. Here, we performed a meta-analysis to evaluate the applications of HPV cDNA as a biomarker in cervical cancer. A systematic literature search was performed using PubMed, Embase, and WANFANG MED ONLINE databases up to March 18, 2019. All literature was analyzed using Meta Disc 1.4 and STATA 14.0 software. Diagnostic measures of accuracy of HPV cDNA in cervical cancer were pooled and investigated. Fifteen studies comprising 684 patients with cervical cancer met our inclusion criteria and were subjected to analysis. The pooled sensitivity and specificity were 0.27 (95% confidence interval [CI], 0.24–0.30) and 0.94(95% CI, 0.92–0.96), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 6.85 (95% CI, 3.09–15.21) and 0.60 (95% CI, 0.46–0.78), respectively. The diagnostic odds ratio was 15.25 (95% CI, 5.42–42.94), and the area under the summary receiver operating characteristic curve was 0.94 (95% CI, 0.89–0.99). There was no significant publication bias observed. In the included studies, HPV cDNA showed clear diagnostic value for diagnosing and monitoring cervical cancer. Our meta-analysis suggested that detection of HPV cDNA in patients with cervical cancer could be used as a noninvasive early dynamic biomarker of tumors, with high specificity and moderate sensitivity. Further large-scale prospective studies are required to validate the factors that may influence the accuracy of cervical cancer diagnosis and monitoring.
format Online
Article
Text
id pubmed-7004305
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-70043052020-02-18 Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis Gu, Yulan Wan, Chuandan Qiu, Jiaming Cui, Yanhong Jiang, Tingwang Zhuang, Zhixiang PLoS One Research Article The applications of liquid biopsy have attracted much attention in biomedical research in recent years. Circulating cell-free DNA (cfDNA) in the serum may serve as a unique tumor marker in various types of cancer. Circulating tumor DNA (ctDNA) is a type of serum cfDNA found in patients with cancer and contains abundant information regarding tumor characteristics, highlighting its potential diagnostic value in the clinical setting. However, the diagnostic value of cfDNA as a biomarker, especially circulating HPV DNA (HPV cDNA) in cervical cancer remains unclear. Here, we performed a meta-analysis to evaluate the applications of HPV cDNA as a biomarker in cervical cancer. A systematic literature search was performed using PubMed, Embase, and WANFANG MED ONLINE databases up to March 18, 2019. All literature was analyzed using Meta Disc 1.4 and STATA 14.0 software. Diagnostic measures of accuracy of HPV cDNA in cervical cancer were pooled and investigated. Fifteen studies comprising 684 patients with cervical cancer met our inclusion criteria and were subjected to analysis. The pooled sensitivity and specificity were 0.27 (95% confidence interval [CI], 0.24–0.30) and 0.94(95% CI, 0.92–0.96), respectively. The pooled positive likelihood ratio and negative likelihood ratio were 6.85 (95% CI, 3.09–15.21) and 0.60 (95% CI, 0.46–0.78), respectively. The diagnostic odds ratio was 15.25 (95% CI, 5.42–42.94), and the area under the summary receiver operating characteristic curve was 0.94 (95% CI, 0.89–0.99). There was no significant publication bias observed. In the included studies, HPV cDNA showed clear diagnostic value for diagnosing and monitoring cervical cancer. Our meta-analysis suggested that detection of HPV cDNA in patients with cervical cancer could be used as a noninvasive early dynamic biomarker of tumors, with high specificity and moderate sensitivity. Further large-scale prospective studies are required to validate the factors that may influence the accuracy of cervical cancer diagnosis and monitoring. Public Library of Science 2020-02-06 /pmc/articles/PMC7004305/ /pubmed/32027658 http://dx.doi.org/10.1371/journal.pone.0224001 Text en © 2020 Gu et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Gu, Yulan
Wan, Chuandan
Qiu, Jiaming
Cui, Yanhong
Jiang, Tingwang
Zhuang, Zhixiang
Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis
title Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis
title_full Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis
title_fullStr Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis
title_full_unstemmed Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis
title_short Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis
title_sort circulating hpv cdna in the blood as a reliable biomarker for cervical cancer: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004305/
https://www.ncbi.nlm.nih.gov/pubmed/32027658
http://dx.doi.org/10.1371/journal.pone.0224001
work_keys_str_mv AT guyulan circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis
AT wanchuandan circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis
AT qiujiaming circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis
AT cuiyanhong circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis
AT jiangtingwang circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis
AT zhuangzhixiang circulatinghpvcdnainthebloodasareliablebiomarkerforcervicalcancerametaanalysis